[go: up one dir, main page]

JP2001518900A - 選択的エストロゲン受容体モジュレーターによる前立腺癌および良性前立腺肥大症の治療または予防 - Google Patents

選択的エストロゲン受容体モジュレーターによる前立腺癌および良性前立腺肥大症の治療または予防

Info

Publication number
JP2001518900A
JP2001518900A JP54316898A JP54316898A JP2001518900A JP 2001518900 A JP2001518900 A JP 2001518900A JP 54316898 A JP54316898 A JP 54316898A JP 54316898 A JP54316898 A JP 54316898A JP 2001518900 A JP2001518900 A JP 2001518900A
Authority
JP
Japan
Prior art keywords
thiophene
benzo
compound
hydroxy
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54316898A
Other languages
English (en)
Japanese (ja)
Inventor
ニューバウアー，ブレイク・リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2001518900A publication Critical patent/JP2001518900A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
JP54316898A 1997-04-09 1998-04-07 選択的エストロゲン受容体モジュレーターによる前立腺癌および良性前立腺肥大症の治療または予防 Pending JP2001518900A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
US60/043,223 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
JP2001518900A true JP2001518900A (ja) 2001-10-16

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54316898A Pending JP2001518900A (ja) 1997-04-09 1998-04-07 選択的エストロゲン受容体モジュレーターによる前立腺癌および良性前立腺肥大症の治療または予防

Country Status (16)

Country Link
EP (1) EP0975629A4 (xx)
JP (1) JP2001518900A (xx)
KR (1) KR20010006218A (xx)
CN (1) CN1259944A (xx)
AU (1) AU6966198A (xx)
BR (1) BR9808515A (xx)
CA (1) CA2286204A1 (xx)
EA (1) EA199900914A1 (xx)
HU (1) HUP0003589A3 (xx)
ID (1) ID24358A (xx)
IL (1) IL132277A0 (xx)
NO (1) NO994903L (xx)
PL (1) PL336205A1 (xx)
TR (1) TR199902701T2 (xx)
WO (1) WO1998045288A1 (xx)
ZA (1) ZA982819B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
RU2261716C1 (ru) * 2004-02-24 2005-10-10 Долженков Сергей Дмитриевич Способ профилактики гнойно-воспалительных осложнений у больных доброкачественной гиперплазией простаты в послеоперационном периоде
BRPI0712103A2 (pt) * 2006-05-22 2012-01-17 Hormos Medical Corp método de tratamento de prostatite não bacteriana crÈnica e para impedir a progressão de hiperplasia prostática benigna (bph) ou cáncer de próstata nos homens
CA2806526C (en) 2007-10-16 2014-12-30 Repros Therapeutics Inc. Trans-clomiphen for type 2 diabetes
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
MY174888A (en) 2013-02-19 2020-05-20 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
IL132953A (en) * 1995-02-28 2002-02-10 Lilly Co Eli Benzothiopene derivatives
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
WO1998045288A1 (en) 1998-10-15
EP0975629A1 (en) 2000-02-02
PL336205A1 (en) 2000-06-05
HUP0003589A3 (en) 2002-02-28
TR199902701T2 (xx) 2000-02-21
ZA982819B (en) 1999-10-04
CA2286204A1 (en) 1998-10-15
AU6966198A (en) 1998-10-30
NO994903L (no) 1999-12-09
IL132277A0 (en) 2001-03-19
NO994903D0 (no) 1999-10-08
EA199900914A1 (ru) 2000-04-24
ID24358A (id) 2000-07-13
HUP0003589A2 (hu) 2002-01-28
KR20010006218A (ko) 2001-01-26
CN1259944A (zh) 2000-07-12
EP0975629A4 (en) 2001-03-21
BR9808515A (pt) 2001-06-19

Similar Documents

Publication Publication Date Title
US6077852A (en) Treatment of central nervous system disorders with selective estrogen receptor modulators
RU2158737C2 (ru) Бензотиофеновые соединения или их фармацевтически приемлемые соли
JPH10506112A (ja) ベンゾチオフェン化合物、組成物、および方法
JPH11511169A (ja) ベンゾチオフェン化合物
PL182493B1 (pl) Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny
JP2001518900A (ja) 選択的エストロゲン受容体モジュレーターによる前立腺癌および良性前立腺肥大症の治療または予防
RU2167158C2 (ru) Производные нафталина или дигидронафталина, фармацевтическая композиция на их основе, способы лечения и промежуточные вещества
JP2001523676A (ja) エストロゲン欠乏症候群の治療に有用な２−アリールベンゾ［ｂ］チオフェン
JP2001518897A (ja) 選択的エストロゲン受容体モジュレーターを用いる乳癌の予防法
US5856340A (en) Method of treating estrogen dependent cancers
CA2214919A1 (en) Benzothiophene compounds, intermediates, processes, compositions, and methods
JPH11504013A (ja) 新規な塩基性側鎖を有するベンゾチオフェン
SI20426A (sl) Nova kristalinična oblika 6-hidroksi-3-(4-(2-(piperidin-1-il) etoksi) fenoksi)-2-(4-metoksifenil) benzo (b) tiofen hidroklorida
JP2002510289A (ja) Ｓｅｒｍとしての活性を持つインデン化合物
CA2207141A1 (en) Benzothiophene compounds, and uses and formulations thereof
US7462647B2 (en) Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
MXPA99009233A (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators
CZ9903554A3 (cs) Způsob léčby nebo profylaxe rakoviny prostaty a benigní hyperplasie prostaty modulátory selektivního receptorů estrogenu
MXPA99009228A (en) Treatment of central nervous system disorders with selective estrogen receptor modulators
CZ9903552A3 (cs) Léčení poruch centrální nervové soustavy selektivními modulátory receptorů estrogenů
MXPA99009234A (en) Prevention of breast cancer with selective estrogen receptor modulators
CZ355399A3 (cs) Léčivo k prevenci karcinomu prsu